Continual and partial MEK inhibition ameliorates cardio-facio-cutaneous phenotypes in zebrafish
- Authors
- Anastasaki, C., Rauen, K.A., and Patton, E.E.
- ID
- ZDB-PUB-120207-3
- Date
- 2012
- Source
- Disease models & mechanisms 5(4): 546-552 (Journal)
- Registered Authors
- Patton, E. Elizabeth
- Keywords
- none
- MeSH Terms
-
- Animals
- Benzamides/chemistry
- Benzamides/pharmacology
- Benzamides/therapeutic use
- Diphenylamine/analogs & derivatives
- Diphenylamine/chemistry
- Diphenylamine/pharmacology
- Diphenylamine/therapeutic use
- Ectodermal Dysplasia/drug therapy*
- Ectodermal Dysplasia/embryology
- Ectodermal Dysplasia/enzymology*
- Ectodermal Dysplasia/pathology
- Embryo, Nonmammalian/drug effects
- Embryo, Nonmammalian/metabolism
- Facies
- Failure to Thrive/drug therapy*
- Failure to Thrive/embryology
- Failure to Thrive/enzymology*
- Failure to Thrive/pathology
- Heart Defects, Congenital/drug therapy*
- Heart Defects, Congenital/embryology
- Heart Defects, Congenital/enzymology*
- Heart Defects, Congenital/pathology
- Mitogen-Activated Protein Kinase Kinases/antagonists & inhibitors*
- Mitogen-Activated Protein Kinase Kinases/metabolism
- Phenotype
- Protein Kinase Inhibitors/chemistry
- Protein Kinase Inhibitors/pharmacology*
- Protein Kinase Inhibitors/therapeutic use*
- Proto-Oncogene Proteins B-raf/metabolism
- Small Molecule Libraries/pharmacology
- Zebrafish/embryology*
- PubMed
- 22301711 Full text @ Dis. Model. Mech.
Cardio-facio-cutaneous (CFC) syndrome is caused by germ-line mutations in RAS, BRAF and MEK. The highly selective and potent MEK inhibitors that have been developed as anti-cancer agents hold potential as therapeutics for CFC syndrome. We have previously shown that the effects of CFC mutations on zebrafish gastrulation can be prevented by a one-hour treatment with MEK inhibitors within a specific developmental time-window. However, MEK activity is essential for normal development and PD0325901 treatment outside this treatment window leads to additional developmental defects in MEK dependent tissues. We now test 10 different doses of PD0325901 at six developmental time points and assess the effects on body axis length, heart development, and craniofacial structures in zebrafish embryos. Notably, we find that a continuous, partial dose of PD0325901 that has only minor inhibition of MEK activity can prevent the action of both the common CFC BRAFQ257R kinase-active allele and the BRAFG596V kinase-impaired mutant allele through the first five days of development. These results provide a detailed study of the effects of PD0325901 in development and show that, unlike in cancer that requires robust inhibition of MAPK signalling, a partial reduction in phospho-ERK activity treatment is sufficient to moderate the developmental effects BRAFCFC mutations.